Dorsal Root Ganglion Stimulation for the Management of Painful Intractable Small Fibre Neuropathy:

Ospedale Regionale di Lugano31 enrolled

Overview

A prospective, single-arm, mono-centre pilot study to obtain preliminary information on the ability of Dorsal Root Ganglion Stimulation (DRGS) in alleviating the painful symptoms in patients with small fiber neuropathy (SFN).

This study is a prospective, single-arm, mono-centre pilot study enrolling a maximum of 31 patients with SFN. All enrolled patients will receive a trial neurostimulation (TNS) lasting from 3 to 30 days and only patients with a positive result in terms of pain intensity reduction will be eligible for the implanted neurostimulation (INS) phase. The target number of patients eligible for INS is 10 and this population will be assessed for impact of DRGS on the neuropathic pain caused by SFN. The expected duration of patients participation will be 14 months. The rationale for this open label approach is that this is a novel technique for which pilot data with regard to applicability and efficacy have yet to be established. Data gathered in the study will provide preliminary data required to assess the feasibility of this intervention, to be used for possible future studies with a more rigorous methodological approach (i.e. controlled trial, randomized controlled trial).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Neuropathy Small Fibre

Interventions

Spinal Modulation Axium™DEVICE

The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation). If during the trial treatment the pain will decrease significantly (\> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years or older at inclusion * Chronic, intractable painful SFN in the peripheral limbs during at least 12 months and a biopsy positive for SFN, with a chronic pain intensity of ≥ 6 on a Numeric Rating Scale (ranging from 0 to 10), for which previous drug therapy was unsuccessful * Stable medication dosage in the 30 days prior to inclusion * Stable pattern of neurological symptoms Exclusion Criteria: * Known or suspected non-compliance * Drug or alcohol abuse * Pain predominantly in upper limbs * Neuropathy or chronic pain in limbs of other origin than SFN * Peripheral vascular disease * Severe foraminal stenosis at the expected target level * Coagulation disorders * Known immune-deficiency * Other significant concomitant diseases and any concomitant malignancies * Presence of other indwelling devices

Locations (1)

EOC Lugano

Lugano, Canton Ticino, Switzerland

RECRUITING

Outcomes

Primary Outcomes

Change in pain intensity assessed by Numeric Rating Scale.

Four assessments/day for 5 consecutive days around the intended measurement timepoint

Time frame: Pain intensity assessment during 2 weeks after inmplatation, at Time point 6 and 12 months after implantation.

Central Contacts

Eva Koetsier, MD PhD LLM

CONTACT

0041918119590 eva.koetsier@eoc.ch

Paolo Maino, MD PhD

CONTACT

0041918119590 paolo.maino@eoc.ch

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.